Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.

Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Götte M. · 2020

Read Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. by Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Götte M. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7242698.txt.

Introduction

Gordon and co-authors show in the lab how remdesivir blocks the copying enzyme of SARS-CoV-2. Their study appeared in the Journal of Biological Chemistry. The virus copies its RNA with an enzyme called RdRp. Remdesivir, a nucleotide look-alike, was the leading candidate against it. Earlier work on Ebola and MERS enzymes suggested it stalls the copying chain.

The team produced the active SARS-CoV-2 enzyme and tested the drug on it. Remdesivir inhibited the enzyme with high potency. Its action fits the delayed chain termination seen in related viruses. Key parts of the enzyme are highly conserved across coronaviruses. The SARS and COVID enzymes are 96 percent identical in their core protein. That conservation explains the drug's broad reach. The findings grounded hopes for remdesivir in hard biochemistry.

Catalog record

CREATORGordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Götte M.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7242698

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency By Calvin J. Gordon, Egor P. Tchesnokov, Emma Woolner, Jason K. Perry, Joy Y. Feng, Danielle P. Porter, Matthias Götte Published in: The Journal of Biological Chemistry DOI: 10.1074/jbc.RA120.013679 ABSTRACT Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the nonstructural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2′-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral. INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)3 is a positive-sense RNA virus and the causative agent of coronavirus disease 2019 (COVID-19) (1, 2). The initial outbreak in December 2019 in Wuhan, China, was declared a pandemic by the World Health Organization on March 10, 2020 (3). Antiviral treatments are urgently needed to relieve the burden on healthcare systems worldwide. Effective therapeutics are expected to reduce mortality and hospitalizations. In the absence of a vaccine, antiviral therapeutics could also be utilized prophylactically to protect vulnerable populations, including those who are frequently exposed to the virus. Despite the earlier outbreaks of SARS in 2003 and Middle East respiratory syndrome (MERS) in 2012, coronavirus-specific antivirals have yet to advance into clinical trials. At this point, the focus is on compounds with a demonstrated broad spectrum of antiviral activities and on drugs developed for other therapeutic purposes with evidence of acting also against coronaviruses. Several of these compounds are currently being assessed in randomized controlled clinical trials, including remdesivir (RDV; formerly GS-5734) (4). RDV is a phosphoramidate prodrug of a 1′-cyano-substituted nucleotide analogue (5). Its triphosphate form (RDV-TP) resembles ATP and is used as a substrate of several viral RNA-dependent RNA polymerase (RdRp) enzymes or complexes (6, 7, 8, 9). The compound has shown broad-spectrum in vitro and in vivo antiviral activity against nonsegmented negative-sense RNA viruses of the Filoviridae (e.g. Ebola virus (EBOV)) (5, 8) and Paramyxoviridae (e.g. Nipah virus (NiV)) families (7, 10, 11), as well as in vitro activity against viruses in the Pneumoviridae (e.g. respiratory syncytial virus (RSV)) family (10). Antiviral activity against a broad spectrum of coronaviruses, including SARS-CoV and MERS-CoV, was subsequently demonstrated both in vitro and in animal models (6, 12, 13, 14, 15). No in vitro inhibition was reported for several segmented negative-sense RNA viruses of the Arenaviridae family (e.g. Lassa virus (LASV)) and the Bunyavirals order (formerly the family Bunyaviridae; e.g. Crimean Congo hemorrhagic fever virus) (10). RDV was also recently tested in a randomized controlled trial during the 2019 Ebola outbreak in the Democratic Republic of the Congo (16). Although two antibody-based treatments showed superior efficacy, mortality in the RDV arm was lower than the overall mortality rate of the outbreak, and human safety data are now available (16). Inhibition of MERS-CoV replication and therapeutic efficacy of RDV was also demonstrated in mouse and rhesus macaque models (13, 15). Progress has been made in elucidating the mechanism of action of RDV-TP. RDV-TP competes with ATP for incorporation by the EBOV RdRp complex composed of the L protein and VP35 (9). Steady-state kinetics reveal that incorporation of ATP is slightly more efficient compared with RDV-TP. In contrast to classic chain terminators, inhibition is not seen immediately following the incorporated RDV-TP, and the existence of a 3′-OH group allows the nucleophilic attack on the next incoming nucleotide. Studies with EBOV RdRp, RSV RdRp, and NiV RdRp have indicated that RNA synthesis is terminated after a few more nucleotide incorporation events (7, 9). RDV-TP incorporation at position i commonly yields delayed chain termination between positions i+3 and i+5. We have recently expressed and purified an active complex composed of MERS nonstructural proteins nsp8 and nsp12 (17). With the limitations of steady-state kinetic measurements, we showed that incorporation of RDV-TP is more efficient than ATP, and delayed chain termination is observed specifically at position i+3. Potential inhibitory effects of RDV-TP on SARS-CoV RdRp or on SARS-CoV-2 RdRp have not been studied. Active SARS-CoV RdRp was shown to form a complex composed of nsp7, nsp8, and nsp12, whereby nsp7 and nsp8 were connected with a linker (18). Structures of complexes with the three subunits were recently determined using cryo-EM (19). Here, we expressed SARS-CoV and SARS-CoV-2 RdRp complexes in insect cells and monitored RNA synthesis on short model primer/templates during elongation. We demonstrate that RDV-TP inhibits SARS-CoV RdRp and SARS-CoV-2 RdRp with the same potency and mechanism of action. The ability to efficiently compete with the natural counterpart ATP is a favorable property of RDV-TP. We have tested in the same context several other nucleotide analogues and commonly observe that incorporation of the natural nucleotide is considerably preferred. Favorable selectivity for the RDV-TP over ATP and delayed chain termination at position i+3 are key elements of a refined mechanism of inhibition observed with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRp complexes. RESULTS Expression of SARS-CoV and SARS-CoV-2 RdRp complexes We have recently generated recombinant MERS-CoV RdRp from a bacmid containing nsp5, -7, -8, and -12 (17). Expression of this construct in insect cells resulted in the nsp5-7-8-12 polyprotein processed by the nsp5 protease. Nickel-nitrilotriacetic acid affinity chromatography yielded an active binary nsp8/12 RdRp complex. We therefore expressed SARS-CoV and SARS-CoV-2 RdRp from bacmids containing the equivalent nsp5, -7, -8, and -12 sequences. This approach yielded binary complexes with nsp8 and nsp12, as described previously for MERS-CoV (17). We also expressed mutant enzymes with amino acid substitutions in the conserved motif C of nsp12 (SDD to SNN) to inactivate the catalytic site (Fig. 1 A). WT and mutant enzymes were tested for RNA synthesis on short model primer/templates mimicking a random elongation complex. Incorporation of a radiolabeled nucleotide allows gel-based detection of reaction products. Whereas WT SARS-CoV and SARS-CoV-2 RdRp complexes were able to synthesize RNA from a 4-mer primer and a 14-mer template, the corresponding active-site mutants showed no template-base–specific nucleotide incorporation (Fig. 1 B). These data confirm that RNA synthesis activity is mediated by nsp12.Figure 1Expression, purification,

Read the complete text